| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 31 | 2026 | 1019 | 5.230 |
Why?
|
| Apoptosis | 39 | 2026 | 1568 | 4.180 |
Why?
|
| Lymphoma | 7 | 2023 | 41 | 2.980 |
Why?
|
| Pyrazoles | 5 | 2026 | 103 | 2.700 |
Why?
|
| Piperidones | 5 | 2022 | 10 | 2.310 |
Why?
|
| Cell Line, Tumor | 38 | 2026 | 2676 | 1.970 |
Why?
|
| Tubulin | 3 | 2026 | 96 | 1.920 |
Why?
|
| Endodeoxyribonucleases | 6 | 2017 | 28 | 1.610 |
Why?
|
| Leukemia | 6 | 2021 | 54 | 1.590 |
Why?
|
| Tubulin Modulators | 2 | 2026 | 20 | 1.180 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2025 | 46 | 1.070 |
Why?
|
| Cell Proliferation | 14 | 2026 | 1455 | 0.950 |
Why?
|
| Drug Screening Assays, Antitumor | 13 | 2026 | 157 | 0.920 |
Why?
|
| MAP Kinase Signaling System | 2 | 2026 | 196 | 0.870 |
Why?
|
| Reactive Oxygen Species | 9 | 2026 | 532 | 0.840 |
Why?
|
| Pyridazines | 2 | 2025 | 16 | 0.820 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 41 | 0.810 |
Why?
|
| Humans | 64 | 2026 | 43102 | 0.790 |
Why?
|
| Awards and Prizes | 1 | 2022 | 28 | 0.760 |
Why?
|
| DNA | 9 | 2011 | 592 | 0.740 |
Why?
|
| Signal Transduction | 9 | 2025 | 2157 | 0.710 |
Why?
|
| Structure-Activity Relationship | 15 | 2026 | 506 | 0.690 |
Why?
|
| Thiazolidinediones | 4 | 2021 | 49 | 0.640 |
Why?
|
| DNA Fragmentation | 7 | 2021 | 98 | 0.630 |
Why?
|
| Deoxyribonucleases | 2 | 2014 | 27 | 0.620 |
Why?
|
| Minority Groups | 3 | 2022 | 690 | 0.620 |
Why?
|
| Membrane Potential, Mitochondrial | 6 | 2025 | 90 | 0.610 |
Why?
|
| DNA-Binding Proteins | 7 | 2002 | 561 | 0.610 |
Why?
|
| Drosophila melanogaster | 2 | 2014 | 193 | 0.600 |
Why?
|
| Naphthyridines | 1 | 2018 | 5 | 0.590 |
Why?
|
| Caspase 3 | 6 | 2025 | 227 | 0.560 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2018 | 116 | 0.540 |
Why?
|
| Burkholderia | 1 | 2017 | 17 | 0.520 |
Why?
|
| Neoplasms | 4 | 2023 | 1377 | 0.490 |
Why?
|
| Animals | 34 | 2025 | 16992 | 0.460 |
Why?
|
| Breast Neoplasms | 4 | 2020 | 1723 | 0.450 |
Why?
|
| Mice | 21 | 2025 | 6644 | 0.430 |
Why?
|
| Amino Acid Sequence | 9 | 2017 | 1180 | 0.430 |
Why?
|
| Histone Deacetylases | 3 | 2025 | 61 | 0.430 |
Why?
|
| Curcumin | 1 | 2016 | 118 | 0.430 |
Why?
|
| Quantum Dots | 2 | 2025 | 38 | 0.420 |
Why?
|
| Ketoconazole | 1 | 2013 | 8 | 0.420 |
Why?
|
| Clotrimazole | 1 | 2013 | 4 | 0.420 |
Why?
|
| Molecular Sequence Data | 12 | 2014 | 1542 | 0.420 |
Why?
|
| Ruthenium | 1 | 2013 | 16 | 0.410 |
Why?
|
| Phosphatidylserines | 4 | 2022 | 22 | 0.410 |
Why?
|
| Enzyme Activation | 3 | 2022 | 462 | 0.400 |
Why?
|
| Cell Cycle | 5 | 2025 | 346 | 0.400 |
Why?
|
| Cell Survival | 11 | 2020 | 945 | 0.400 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2022 | 152 | 0.390 |
Why?
|
| Stress, Physiological | 1 | 2014 | 172 | 0.390 |
Why?
|
| Bacterial Proteins | 1 | 2017 | 595 | 0.370 |
Why?
|
| Science | 1 | 2012 | 24 | 0.370 |
Why?
|
| Career Choice | 1 | 2012 | 52 | 0.360 |
Why?
|
| Melanoma | 2 | 2023 | 110 | 0.350 |
Why?
|
| Homeodomain Proteins | 3 | 1998 | 150 | 0.350 |
Why?
|
| Molecular Structure | 8 | 2025 | 570 | 0.350 |
Why?
|
| Evolution, Molecular | 2 | 2017 | 307 | 0.350 |
Why?
|
| Organotin Compounds | 1 | 2010 | 2 | 0.340 |
Why?
|
| Mentors | 1 | 2012 | 145 | 0.340 |
Why?
|
| Sequence Alignment | 4 | 2017 | 272 | 0.330 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2020 | 127 | 0.330 |
Why?
|
| Ruthenium Compounds | 1 | 2010 | 2 | 0.330 |
Why?
|
| Cultural Diversity | 1 | 2012 | 193 | 0.330 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2024 | 968 | 0.320 |
Why?
|
| Sequence Homology, Amino Acid | 6 | 2017 | 267 | 0.320 |
Why?
|
| Lactoferrin | 2 | 2020 | 9 | 0.320 |
Why?
|
| Caspases | 2 | 2022 | 148 | 0.320 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2026 | 1124 | 0.310 |
Why?
|
| Phylogeny | 2 | 2017 | 769 | 0.300 |
Why?
|
| Drug Design | 2 | 2021 | 186 | 0.300 |
Why?
|
| Carbon | 3 | 2025 | 128 | 0.300 |
Why?
|
| Ubiquitinated Proteins | 2 | 2019 | 6 | 0.290 |
Why?
|
| Propranolol | 2 | 2019 | 18 | 0.280 |
Why?
|
| Neoplasm Proteins | 2 | 2022 | 228 | 0.280 |
Why?
|
| Autoantibodies | 2 | 2022 | 117 | 0.280 |
Why?
|
| Biological Assay | 2 | 2005 | 63 | 0.270 |
Why?
|
| Repressor Proteins | 2 | 2021 | 273 | 0.270 |
Why?
|
| Promoter Regions, Genetic | 3 | 2002 | 526 | 0.270 |
Why?
|
| Hydroquinones | 2 | 2020 | 10 | 0.270 |
Why?
|
| Endonucleases | 3 | 1997 | 18 | 0.270 |
Why?
|
| Inhibitory Concentration 50 | 4 | 2018 | 99 | 0.270 |
Why?
|
| Muramidase | 2 | 2025 | 30 | 0.270 |
Why?
|
| Microscopy, Fluorescence | 2 | 2005 | 256 | 0.260 |
Why?
|
| Nuclear Proteins | 5 | 2015 | 333 | 0.260 |
Why?
|
| Lysosomes | 1 | 2007 | 86 | 0.260 |
Why?
|
| Jurkat Cells | 2 | 2025 | 87 | 0.260 |
Why?
|
| Gene Expression Regulation | 3 | 2006 | 1070 | 0.260 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2022 | 163 | 0.260 |
Why?
|
| Flow Cytometry | 3 | 2016 | 411 | 0.260 |
Why?
|
| Female | 14 | 2026 | 24698 | 0.250 |
Why?
|
| Recombination, Genetic | 5 | 1997 | 95 | 0.250 |
Why?
|
| Hordeum | 2 | 2019 | 15 | 0.250 |
Why?
|
| Base Sequence | 11 | 2002 | 983 | 0.250 |
Why?
|
| Liver Neoplasms | 2 | 2022 | 224 | 0.250 |
Why?
|
| Glucose Transporter Type 1 | 3 | 2020 | 20 | 0.240 |
Why?
|
| Gene Expression Profiling | 2 | 2022 | 704 | 0.240 |
Why?
|
| Temperature | 3 | 2019 | 313 | 0.240 |
Why?
|
| Green Fluorescent Proteins | 2 | 2010 | 209 | 0.240 |
Why?
|
| Pyridinium Compounds | 1 | 2026 | 29 | 0.240 |
Why?
|
| Hela Cells | 7 | 2021 | 376 | 0.240 |
Why?
|
| 4-Quinolones | 1 | 2025 | 1 | 0.240 |
Why?
|
| Arthritis, Experimental | 1 | 2025 | 8 | 0.230 |
Why?
|
| Phosphorylation | 4 | 2022 | 986 | 0.230 |
Why?
|
| DNA Damage | 1 | 2007 | 356 | 0.230 |
Why?
|
| Neuropeptide Y | 1 | 2025 | 25 | 0.230 |
Why?
|
| Necrosis | 2 | 2019 | 54 | 0.230 |
Why?
|
| Immunity, Innate | 1 | 2006 | 171 | 0.230 |
Why?
|
| Sirolimus | 1 | 2025 | 70 | 0.220 |
Why?
|
| Quinones | 1 | 2004 | 17 | 0.220 |
Why?
|
| Prostatic Neoplasms | 2 | 2013 | 1092 | 0.220 |
Why?
|
| Toxicity Tests | 1 | 2004 | 44 | 0.220 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2025 | 58 | 0.220 |
Why?
|
| Agriculture | 1 | 2005 | 66 | 0.220 |
Why?
|
| Amyloid | 1 | 2025 | 65 | 0.210 |
Why?
|
| Binding Sites | 6 | 2021 | 671 | 0.210 |
Why?
|
| Pyrimidines | 1 | 2025 | 139 | 0.210 |
Why?
|
| Nitrogen | 1 | 2025 | 84 | 0.210 |
Why?
|
| Thiophenes | 1 | 2023 | 32 | 0.200 |
Why?
|
| Bacteria | 2 | 2011 | 293 | 0.200 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2022 | 79 | 0.200 |
Why?
|
| Eukaryotic Cells | 2 | 2017 | 35 | 0.200 |
Why?
|
| Graphite | 1 | 2024 | 64 | 0.200 |
Why?
|
| Biomedical Research | 2 | 2022 | 502 | 0.190 |
Why?
|
| Cloning, Molecular | 5 | 2014 | 314 | 0.190 |
Why?
|
| Enzyme Inhibitors | 1 | 2025 | 458 | 0.190 |
Why?
|
| Antibodies, Neoplasm | 1 | 2022 | 20 | 0.190 |
Why?
|
| Molecular Dynamics Simulation | 2 | 2025 | 188 | 0.190 |
Why?
|
| Cell Death | 2 | 2022 | 278 | 0.190 |
Why?
|
| Surface-Active Agents | 2 | 2013 | 46 | 0.190 |
Why?
|
| Ionic Liquids | 1 | 2022 | 20 | 0.180 |
Why?
|
| Models, Molecular | 5 | 2020 | 876 | 0.180 |
Why?
|
| Sp1 Transcription Factor | 1 | 2002 | 46 | 0.180 |
Why?
|
| Drosophila | 2 | 2002 | 152 | 0.180 |
Why?
|
| Oximes | 1 | 2021 | 7 | 0.180 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2021 | 33 | 0.180 |
Why?
|
| Antigens, Neoplasm | 1 | 2022 | 90 | 0.180 |
Why?
|
| Activating Transcription Factor 3 | 1 | 2021 | 3 | 0.180 |
Why?
|
| Exocytosis | 1 | 2022 | 49 | 0.180 |
Why?
|
| Copper | 2 | 2017 | 134 | 0.180 |
Why?
|
| Heme Oxygenase-1 | 1 | 2021 | 52 | 0.180 |
Why?
|
| Biocompatible Materials | 3 | 2025 | 108 | 0.180 |
Why?
|
| Risk-Taking | 1 | 2005 | 457 | 0.170 |
Why?
|
| Cell Line | 8 | 2020 | 1410 | 0.170 |
Why?
|
| Thiadiazoles | 1 | 2021 | 6 | 0.170 |
Why?
|
| Prostate | 1 | 2022 | 155 | 0.170 |
Why?
|
| PPAR gamma | 1 | 2021 | 55 | 0.170 |
Why?
|
| Microtubules | 1 | 2022 | 121 | 0.170 |
Why?
|
| Oxidative Stress | 2 | 2019 | 1003 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 1 | 2022 | 290 | 0.170 |
Why?
|
| Glucose Transport Proteins, Facilitative | 1 | 2020 | 13 | 0.170 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2019 | 54 | 0.170 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2020 | 31 | 0.160 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2020 | 14 | 0.160 |
Why?
|
| Mutation | 4 | 2020 | 1177 | 0.160 |
Why?
|
| Up-Regulation | 3 | 2018 | 536 | 0.160 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 178 | 0.160 |
Why?
|
| Oxidative Phosphorylation | 1 | 2020 | 60 | 0.160 |
Why?
|
| Aromatase Inhibitors | 1 | 2020 | 19 | 0.160 |
Why?
|
| Caenorhabditis elegans | 1 | 2000 | 80 | 0.150 |
Why?
|
| Inflammation | 1 | 2025 | 758 | 0.150 |
Why?
|
| Needles | 1 | 2019 | 10 | 0.150 |
Why?
|
| Sulfonamides | 1 | 2020 | 91 | 0.150 |
Why?
|
| Protein Conformation | 2 | 2017 | 416 | 0.150 |
Why?
|
| Thyroid Gland | 1 | 2019 | 23 | 0.150 |
Why?
|
| Colonic Neoplasms | 1 | 2021 | 223 | 0.150 |
Why?
|
| Drug Monitoring | 1 | 2020 | 69 | 0.150 |
Why?
|
| Microvessels | 1 | 2019 | 31 | 0.150 |
Why?
|
| Organometallic Compounds | 2 | 2011 | 71 | 0.150 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2017 | 388 | 0.150 |
Why?
|
| src-Family Kinases | 1 | 2019 | 49 | 0.150 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2019 | 76 | 0.150 |
Why?
|
| Crystallography, X-Ray | 2 | 2017 | 280 | 0.150 |
Why?
|
| B-Lymphocytes | 3 | 1996 | 189 | 0.150 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2018 | 8 | 0.140 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 50 | 0.140 |
Why?
|
| Polyubiquitin | 1 | 2018 | 7 | 0.140 |
Why?
|
| Mitochondria | 2 | 2020 | 523 | 0.140 |
Why?
|
| Unfolded Protein Response | 1 | 2018 | 22 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2019 | 124 | 0.140 |
Why?
|
| Molecular Weight | 1 | 2018 | 168 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2019 | 183 | 0.140 |
Why?
|
| Biological Transport | 1 | 2018 | 204 | 0.140 |
Why?
|
| Spleen | 2 | 1997 | 204 | 0.140 |
Why?
|
| Plant Extracts | 2 | 2019 | 302 | 0.140 |
Why?
|
| Cell Movement | 1 | 2022 | 655 | 0.140 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 495 | 0.140 |
Why?
|
| RNA-Binding Proteins | 2 | 1998 | 161 | 0.130 |
Why?
|
| Prokaryotic Cells | 1 | 2017 | 9 | 0.130 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2017 | 24 | 0.130 |
Why?
|
| Genes, Switch | 1 | 1997 | 3 | 0.130 |
Why?
|
| Proteins | 2 | 1997 | 382 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 299 | 0.130 |
Why?
|
| Catalytic Domain | 1 | 2017 | 118 | 0.130 |
Why?
|
| Recombinant Proteins | 4 | 2020 | 518 | 0.130 |
Why?
|
| Students | 1 | 2022 | 626 | 0.130 |
Why?
|
| Protein Folding | 1 | 2017 | 123 | 0.120 |
Why?
|
| DNA, Bacterial | 1 | 2017 | 206 | 0.120 |
Why?
|
| Imidazoles | 2 | 2021 | 142 | 0.120 |
Why?
|
| Immunoglobulin Switch Region | 1 | 1996 | 3 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2017 | 296 | 0.120 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1996 | 36 | 0.120 |
Why?
|
| Endothelial Cells | 1 | 2019 | 329 | 0.120 |
Why?
|
| Cells, Cultured | 4 | 2013 | 1621 | 0.120 |
Why?
|
| DNA, Neoplasm | 2 | 2013 | 92 | 0.120 |
Why?
|
| Male | 7 | 2025 | 23409 | 0.110 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 1995 | 2 | 0.110 |
Why?
|
| Transcription Factors | 4 | 2002 | 735 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 1081 | 0.110 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1995 | 49 | 0.110 |
Why?
|
| Intracellular Space | 1 | 2014 | 37 | 0.110 |
Why?
|
| Cations | 1 | 2014 | 50 | 0.110 |
Why?
|
| Protein Biosynthesis | 1 | 1995 | 132 | 0.110 |
Why?
|
| Adenosine Triphosphate | 1 | 1995 | 206 | 0.110 |
Why?
|
| High-Throughput Screening Assays | 1 | 2014 | 74 | 0.100 |
Why?
|
| Piperidines | 1 | 2014 | 83 | 0.100 |
Why?
|
| Protein Transport | 1 | 2014 | 296 | 0.100 |
Why?
|
| Xylose | 1 | 2013 | 12 | 0.100 |
Why?
|
| Phosphoproteins | 1 | 1995 | 206 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 2 | 2007 | 515 | 0.100 |
Why?
|
| Escherichia coli | 2 | 2006 | 460 | 0.100 |
Why?
|
| Surface Properties | 3 | 2024 | 160 | 0.100 |
Why?
|
| Triazoles | 1 | 2013 | 102 | 0.090 |
Why?
|
| Cerium | 1 | 2012 | 18 | 0.090 |
Why?
|
| Alginates | 1 | 2012 | 20 | 0.090 |
Why?
|
| Research Support as Topic | 1 | 2012 | 89 | 0.090 |
Why?
|
| Phosphines | 1 | 2011 | 6 | 0.090 |
Why?
|
| Glycosides | 1 | 2011 | 23 | 0.090 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2013 | 134 | 0.090 |
Why?
|
| Benzylidene Compounds | 1 | 2011 | 6 | 0.090 |
Why?
|
| Cytotoxins | 1 | 2011 | 11 | 0.090 |
Why?
|
| Platinum | 1 | 2011 | 23 | 0.090 |
Why?
|
| Alkenes | 1 | 2011 | 17 | 0.090 |
Why?
|
| Palladium | 1 | 2011 | 30 | 0.090 |
Why?
|
| Coordination Complexes | 1 | 2011 | 28 | 0.090 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2011 | 97 | 0.090 |
Why?
|
| Gene Expression | 1 | 2014 | 701 | 0.090 |
Why?
|
| Titanium | 1 | 2011 | 48 | 0.090 |
Why?
|
| Intercalating Agents | 1 | 2010 | 13 | 0.080 |
Why?
|
| Annexin A5 | 1 | 2010 | 27 | 0.080 |
Why?
|
| Propidium | 1 | 2010 | 20 | 0.080 |
Why?
|
| Sulfides | 1 | 2011 | 78 | 0.080 |
Why?
|
| Amides | 1 | 2011 | 71 | 0.080 |
Why?
|
| Soil Pollutants | 1 | 2012 | 105 | 0.080 |
Why?
|
| Fungi | 2 | 2011 | 106 | 0.080 |
Why?
|
| Anti-Infective Agents | 1 | 2011 | 75 | 0.080 |
Why?
|
| Zea mays | 1 | 2012 | 76 | 0.080 |
Why?
|
| Mice, SCID | 2 | 2021 | 158 | 0.080 |
Why?
|
| Chloroquine | 1 | 2010 | 19 | 0.080 |
Why?
|
| HIV Infections | 1 | 2005 | 2586 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 449 | 0.080 |
Why?
|
| Host-Parasite Interactions | 1 | 2010 | 79 | 0.080 |
Why?
|
| Organogold Compounds | 1 | 2009 | 3 | 0.080 |
Why?
|
| Plasmids | 2 | 2007 | 244 | 0.070 |
Why?
|
| Immunoglobulins | 2 | 1986 | 39 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 174 | 0.070 |
Why?
|
| Immunoglobulin Variable Region | 2 | 1987 | 22 | 0.070 |
Why?
|
| Metal Nanoparticles | 1 | 2012 | 230 | 0.070 |
Why?
|
| Trypanosoma cruzi | 1 | 2010 | 157 | 0.070 |
Why?
|
| Fibroblasts | 1 | 2010 | 281 | 0.070 |
Why?
|
| Immunoglobulin Joining Region | 1 | 1987 | 4 | 0.070 |
Why?
|
| Amoeba | 1 | 2007 | 6 | 0.070 |
Why?
|
| Eukaryota | 1 | 2007 | 20 | 0.070 |
Why?
|
| Micrococcus luteus | 1 | 2006 | 4 | 0.060 |
Why?
|
| Hemocytes | 1 | 2006 | 11 | 0.060 |
Why?
|
| Plants | 1 | 2007 | 113 | 0.060 |
Why?
|
| Liposomes | 1 | 2007 | 132 | 0.060 |
Why?
|
| Bacterial Infections | 1 | 2006 | 45 | 0.060 |
Why?
|
| Plasmacytoma | 1 | 1985 | 11 | 0.060 |
Why?
|
| Genes, Regulator | 1 | 1985 | 27 | 0.060 |
Why?
|
| Substrate Specificity | 2 | 1997 | 219 | 0.060 |
Why?
|
| Mycobacterium avium | 1 | 2005 | 4 | 0.060 |
Why?
|
| Fluorometry | 1 | 2005 | 17 | 0.060 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 2 | 1996 | 4 | 0.060 |
Why?
|
| Enhancer Elements, Genetic | 1 | 1985 | 64 | 0.060 |
Why?
|
| Chromosome Deletion | 1 | 1985 | 53 | 0.060 |
Why?
|
| Indicators and Reagents | 1 | 2005 | 61 | 0.060 |
Why?
|
| Mice, Inbred DBA | 1 | 2025 | 73 | 0.060 |
Why?
|
| Middle Aged | 4 | 2020 | 12222 | 0.060 |
Why?
|
| RNA Interference | 1 | 2006 | 247 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2020 | 1600 | 0.060 |
Why?
|
| Acetophenones | 1 | 2005 | 10 | 0.060 |
Why?
|
| Naphthoquinones | 1 | 2005 | 41 | 0.060 |
Why?
|
| Mycobacterium | 1 | 2005 | 16 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2006 | 1271 | 0.050 |
Why?
|
| Transients and Migrants | 1 | 2005 | 42 | 0.050 |
Why?
|
| Safe Sex | 1 | 2005 | 78 | 0.050 |
Why?
|
| Models, Chemical | 1 | 2005 | 204 | 0.050 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2005 | 171 | 0.050 |
Why?
|
| Data Collection | 1 | 2005 | 210 | 0.050 |
Why?
|
| Autophagy | 1 | 2025 | 140 | 0.050 |
Why?
|
| Transfection | 3 | 2007 | 532 | 0.050 |
Why?
|
| Mexico | 1 | 2005 | 298 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2019 | 1604 | 0.050 |
Why?
|
| Phototherapy | 1 | 2023 | 25 | 0.050 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2023 | 83 | 0.050 |
Why?
|
| Particle Size | 1 | 2024 | 272 | 0.050 |
Why?
|
| Cattle | 2 | 2011 | 498 | 0.050 |
Why?
|
| Receptors, Polymeric Immunoglobulin | 1 | 2002 | 2 | 0.050 |
Why?
|
| Texas | 1 | 2005 | 457 | 0.050 |
Why?
|
| Genes, Insect | 1 | 2002 | 27 | 0.050 |
Why?
|
| Neurodegenerative Diseases | 1 | 2024 | 141 | 0.050 |
Why?
|
| Light | 1 | 2023 | 185 | 0.050 |
Why?
|
| Sp3 Transcription Factor | 1 | 2002 | 8 | 0.050 |
Why?
|
| Administration, Cutaneous | 1 | 2022 | 48 | 0.050 |
Why?
|
| Caprylates | 1 | 2022 | 14 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2022 | 120 | 0.050 |
Why?
|
| Minority Health | 1 | 2022 | 95 | 0.050 |
Why?
|
| Chromosome Mapping | 1 | 2002 | 199 | 0.050 |
Why?
|
| Mutation, Missense | 1 | 2002 | 91 | 0.050 |
Why?
|
| Choline | 1 | 2022 | 61 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2020 | 2544 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2002 | 186 | 0.040 |
Why?
|
| Proteome | 1 | 2022 | 152 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2021 | 98 | 0.040 |
Why?
|
| Research Personnel | 1 | 2022 | 206 | 0.040 |
Why?
|
| Benzyl Compounds | 1 | 2021 | 3 | 0.040 |
Why?
|
| Neuroprotective Agents | 1 | 2024 | 269 | 0.040 |
Why?
|
| Skin | 1 | 2022 | 187 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2005 | 432 | 0.040 |
Why?
|
| Saccharomycetales | 1 | 2020 | 8 | 0.040 |
Why?
|
| Cosmids | 1 | 2000 | 2 | 0.040 |
Why?
|
| DNA, Recombinant | 1 | 2000 | 17 | 0.040 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2021 | 110 | 0.040 |
Why?
|
| Genetic Complementation Test | 1 | 2000 | 56 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2021 | 173 | 0.040 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2000 | 88 | 0.040 |
Why?
|
| Neoplasms, Experimental | 1 | 2020 | 38 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2000 | 79 | 0.040 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2020 | 19 | 0.040 |
Why?
|
| Models, Biological | 1 | 2003 | 712 | 0.040 |
Why?
|
| Adult | 3 | 2019 | 13872 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 3156 | 0.040 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2020 | 68 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2020 | 139 | 0.040 |
Why?
|
| Pichia | 1 | 2019 | 10 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2005 | 638 | 0.040 |
Why?
|
| Thyroid Nodule | 1 | 2019 | 4 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2019 | 13 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 59 | 0.040 |
Why?
|
| Cell Shape | 1 | 2019 | 42 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 2 | 1995 | 694 | 0.040 |
Why?
|
| Postmenopause | 1 | 2020 | 141 | 0.040 |
Why?
|
| Equipment Design | 1 | 2019 | 145 | 0.040 |
Why?
|
| Materials Testing | 1 | 2019 | 101 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2019 | 100 | 0.040 |
Why?
|
| Free Radical Scavengers | 1 | 2019 | 64 | 0.040 |
Why?
|
| Ligands | 2 | 2011 | 388 | 0.040 |
Why?
|
| Fibrosis | 1 | 2019 | 169 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 184 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 1998 | 93 | 0.030 |
Why?
|
| Hydrogen Peroxide | 1 | 2019 | 190 | 0.030 |
Why?
|
| Phenols | 1 | 2019 | 107 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 861 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2011 | 245 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 1067 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 1997 | 64 | 0.030 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 1997 | 26 | 0.030 |
Why?
|
| Receptors, Adrenergic, beta-3 | 1 | 2017 | 3 | 0.030 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2017 | 3 | 0.030 |
Why?
|
| Consensus Sequence | 1 | 1997 | 21 | 0.030 |
Why?
|
| Cations, Divalent | 1 | 1997 | 25 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 34 | 0.030 |
Why?
|
| Nervous System | 1 | 1997 | 32 | 0.030 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2017 | 52 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 1997 | 146 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2017 | 137 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 374 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2017 | 161 | 0.030 |
Why?
|
| Mitogens | 1 | 1995 | 10 | 0.030 |
Why?
|
| Cytokines | 1 | 2019 | 678 | 0.030 |
Why?
|
| Deoxyribonucleotides | 1 | 1995 | 11 | 0.030 |
Why?
|
| Immunologic Tests | 1 | 2015 | 11 | 0.030 |
Why?
|
| VDJ Recombinases | 1 | 1995 | 2 | 0.030 |
Why?
|
| Marine Toxins | 1 | 1995 | 17 | 0.030 |
Why?
|
| Oxazoles | 1 | 1995 | 19 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2015 | 80 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 196 | 0.030 |
Why?
|
| Antibodies | 1 | 1995 | 144 | 0.030 |
Why?
|
| Autoantigens | 1 | 2015 | 87 | 0.030 |
Why?
|
| Protein Phosphatase 1 | 1 | 1995 | 70 | 0.030 |
Why?
|
| HL-60 Cells | 1 | 2014 | 33 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 1997 | 592 | 0.030 |
Why?
|
| Dimerization | 1 | 2014 | 112 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 458 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 1995 | 239 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 1995 | 455 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 611 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2014 | 108 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2015 | 883 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 934 | 0.020 |
Why?
|
| X-Ray Absorption Spectroscopy | 1 | 2012 | 7 | 0.020 |
Why?
|
| Hexuronic Acids | 1 | 2012 | 8 | 0.020 |
Why?
|
| Glucuronic Acid | 1 | 2012 | 8 | 0.020 |
Why?
|
| Plant Shoots | 1 | 2012 | 25 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2014 | 258 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 1857 | 0.020 |
Why?
|
| Carbohydrate Conformation | 1 | 2011 | 15 | 0.020 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2011 | 31 | 0.020 |
Why?
|
| Alkylation | 1 | 2011 | 11 | 0.020 |
Why?
|
| United States | 1 | 2022 | 5205 | 0.020 |
Why?
|
| Circular Dichroism | 1 | 2011 | 64 | 0.020 |
Why?
|
| Protein Binding | 1 | 1995 | 1082 | 0.020 |
Why?
|
| Catalysis | 1 | 2011 | 187 | 0.020 |
Why?
|
| Nucleic Acid Conformation | 1 | 2011 | 154 | 0.020 |
Why?
|
| Automation | 1 | 2010 | 22 | 0.020 |
Why?
|
| Soil | 1 | 2012 | 171 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2010 | 64 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 301 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2011 | 457 | 0.020 |
Why?
|
| Plant Roots | 1 | 2012 | 180 | 0.020 |
Why?
|
| Neurons | 1 | 1997 | 1263 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 317 | 0.020 |
Why?
|
| Phosphoranes | 1 | 2009 | 3 | 0.020 |
Why?
|
| Thioredoxin-Disulfide Reductase | 1 | 2009 | 7 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2009 | 48 | 0.020 |
Why?
|
| Solubility | 1 | 2009 | 139 | 0.020 |
Why?
|
| Aging | 1 | 2014 | 783 | 0.020 |
Why?
|
| Software | 1 | 2010 | 236 | 0.020 |
Why?
|
| Drug Stability | 1 | 2009 | 129 | 0.020 |
Why?
|
| Genes, Immunoglobulin | 1 | 1987 | 37 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2007 | 160 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2007 | 165 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2011 | 367 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 1869 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 1985 | 65 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 277 | 0.010 |
Why?
|
| Alleles | 1 | 1985 | 352 | 0.010 |
Why?
|
| Kidney | 1 | 2007 | 372 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 8214 | 0.010 |
Why?
|
| DNA Footprinting | 1 | 2002 | 8 | 0.010 |
Why?
|
| Electrophoresis | 1 | 2002 | 24 | 0.010 |
Why?
|
| HT29 Cells | 1 | 2002 | 60 | 0.010 |
Why?
|
| Caco-2 Cells | 1 | 2002 | 64 | 0.010 |
Why?
|
| CHO Cells | 1 | 2002 | 123 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2002 | 148 | 0.010 |
Why?
|
| Cricetinae | 1 | 2002 | 241 | 0.010 |
Why?
|
| Immunoglobulin J Recombination Signal Sequence-Binding Protein | 1 | 1997 | 1 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 1997 | 48 | 0.010 |
Why?
|
| Receptor, Notch1 | 1 | 1997 | 16 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 1997 | 83 | 0.010 |
Why?
|
| Homozygote | 1 | 1997 | 77 | 0.010 |
Why?
|
| Morphogenesis | 1 | 1997 | 48 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1997 | 138 | 0.010 |
Why?
|
| Mammals | 1 | 1997 | 112 | 0.010 |
Why?
|
| Spinal Cord | 1 | 1997 | 114 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 1997 | 200 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1997 | 383 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1997 | 638 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 1997 | 561 | 0.010 |
Why?
|
| Brain | 1 | 1997 | 1472 | 0.000 |
Why?
|
| Bursa of Fabricius | 1 | 1986 | 3 | 0.000 |
Why?
|
| Immunoglobulin J-Chains | 1 | 1986 | 3 | 0.000 |
Why?
|
| Chick Embryo | 1 | 1986 | 79 | 0.000 |
Why?
|
| Liver | 1 | 1986 | 511 | 0.000 |
Why?
|